News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
MediGene, Inc. Drug Extends Pancreatic Cancer Survival
September 16, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 16 (Reuters) - Patients with inoperable pancreatic cancer live substantially longer when given MediGene's experimental drug EndoTAG-1 on top of standard chemotherapy, according to clinical trial results.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Europe
AstraZeneca Suspends $270M UK Commitment Months After Scrapping Vaccine Facility
September 15, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Capsida Reports Patient Death in Gene Therapy Trial
September 11, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
September 11, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees
September 11, 2025
·
1 min read
·
Tristan Manalac
